Literature DB >> 7740014

Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial.

M Kornitzer1, M Boutsen, M Dramaix, J Thijs, G Gustavsson.   

Abstract

BACKGROUND: Smoking is considered as an addiction to nicotine for most subjects consuming 10 cigarettes or more per day. Hence, nicotine replacement therapy by way of gum, patch, or spray has been advocated. The rationale of this study is to evaluate the possible beneficial effects of adding nicotine gum to the routine of subjects using the nicotine patch. The effect of the nicotine patch against the placebo, both groups receiving placebo nicotine gum, has also been assessed.
METHODS: Healthy subjects (374) were randomized at their work-setting in a 1-year double-blind placebo-controlled trial: 149 subjects to active nicotine patch + active gum (group 1), 150 to active nicotine patch + placebo gum (group 2), and 75 to placebo patch + gum (group 3). Treatment duration was 12 weeks with a 16-hr transdermal patch of 15 mg, followed by a 6 + 6-weeks weaning period on respectively 10 and 5 mg patches. Gum use was not restricted during the first 6 months, with recommendations to use at least four pieces a day. A strict definition of smoking abstinence was used in this study, which did not allow smoking any cigarette after Week 1. Nonsmoking status at each visit, as reported by the subjects, was verified by CO below 10 ppm in expired air.
RESULTS: Abstinence rates in group 1 against group 2 were 34.2 and 22.7% (P = 0.027) at 12 weeks, 27.5 and 15.3% (P = 0.010) at 24 weeks, and 18.1 and 12.7% (P = 0.191) at 52 weeks. In group 3, abstinence rates were 17.3, 14.7, and 13.3% respectively at 12, 24, and 52 weeks. Using logistic regression with adjustment for six baseline covariates, odds ratios for abstinence (with 95% CI) were computed. For group 1/group 2, OR at 12, 24, and 52 weeks were 1.72 (1.03-2.94) (P = 0.039), 2.04 (1.14-3.57) (P = 0.018), and 1.47 (0.76-2.76) (P = 0.125). No significant differences in OR were observed when comparing groups 2 and 3. Time to relapse is significantly longer in group 1 as compared to that of group 2 (P = 0.041), whereas no significant differences between groups 2 and 3 were observed. No significant differences between the three groups in systemic and local adverse drug events were observed.
CONCLUSION: Adding active gum use to active patch use in subjects smoking 10 cigarettes or more a day increased abstinence rates, which are statistically significant up to 24 weeks.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7740014     DOI: 10.1006/pmed.1995.1006

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  44 in total

1.  Smoking cessation guidelines for health professionals. A guide to effective smoking cessation interventions for the health care system. Health Education Authority.

Authors:  M Raw; A McNeill; R West
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

Review 2.  Smoking cessation.

Authors:  I A Campbell
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 3.  Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability.

Authors:  C T Sweeney; R V Fant; K O Fagerstrom; J F McGovern; J E Henningfield
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 4.  Medications for smoking cessation.

Authors:  Robin L Corelli; Karen Suchanek Hudmon
Journal:  West J Med       Date:  2002-03

Review 5.  Current approaches to the management of smoking cessation.

Authors:  Gay Sutherland
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  A review of smoking cessation interventions.

Authors:  Ashish Maseeh; Gagandeep Kwatra
Journal:  MedGenMed       Date:  2005-06-07

7.  Preferences among four combination nicotine treatments.

Authors:  Nina G Schneider; Margaret A Koury; Chris Cortner; Richard E Olmstead; Neil Hartman; Leonard Kleinman; Andrew Kim; Craig Chaya; David Leaf
Journal:  Psychopharmacology (Berl)       Date:  2006-08-01       Impact factor: 4.530

Review 8.  Pharmacotherapy for tobacco cessation: nicotine agonists, antagonists, and partial agonists.

Authors:  Maher Karam-Hage; Paul M Cinciripini
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

Review 9.  The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments.

Authors:  N G Schneider; R E Olmstead; M A Franzon; E Lunell
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 10.  The benefits of stopping smoking and the role of nicotine replacement therapy in older patients.

Authors:  S G Gourlay; N L Benowitz
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.